Incyte Corporation (INCY) Earnings Cruise on Jakafi Growth

Baricitinib (JAK1 and JAK2)

• In development with Eli Lilly & Co. (NYSE:LLY) for various autoimmune indications, the drug is currently being evaluated in a phase 3 trial for rheumatoid arthritis. If all goes well, it will be the second product launched by Incyte and should go a long way is cementing the company’s status in the JAK inhibitor space.
• Currently, Pfizer Inc. (NYSE:PFE) wields the only JAK inhibitor (Xeljanz) approved for rheumatoid arthritis. Baricitinib is a good bet to shake up the market in the next few years and is also being evaluated in two additional phase 2 trials for psoriasis and diabetic nephropathy.

The ongoing trials for Jakafi are crucial for maximizing the drug’s potential. Expanding into PV and pancreatic cancer would give Incyte and Novartis a powerful next-generation multi-cancer treatment option for patients and shareholders. Additionally, investors cannot forget about baricitinib, which has massive potential for the company in autoimmune diseases. Earlier-stage trials are ongoing that could eventually have big potential, but realistically speaking they shouldn’t be movers for several years.

Foolish bottom line
Investors should get a boost from the great second-quarter results announced on Wednesday, but the majority of the potential lies in the pipeline. The good news is that all trials are progressing as planned and making early headway. The most immediate movers for Incyte stock will surely be the phase 3 trial data release later this quarter and additional approvals for Jakafi. Next up will be results from baricitinib — an important potential second product for the company. Given the impressive future potential, I will certainly look to add shares to my personal portfolio in the next year. Will you be joining me?

The article Incyte Earnings Cruise on Jakafi Growth originally appeared on Fool.com and is written by Maxx Chatsko.

Fool contributor Maxx Chatsko has no position in any stocks mentioned. Check out his personal portfolio, his CAPS page, or follow him on Twitter @BlacknGoldFool to keep up with his writing on energy, bioprocessing, and biotechnology. The Motley Fool has no position in any of the stocks mentioned.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.